PDCD1 and myeloid sarcoma: It was found that miR-16, miR-155, and miR-142-3p on T cells were significantly upregulated in MS patients who failed to respond to first-line therapy, while the expressions of FoxP3, FoxO1, PDCD1, and IRF2BP2 were notably decreased.